QBW276

Drug Novartis Pharmaceuticals Corporation
Total Payments
$476,294
Transactions
21
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $28,866 2 0
2018 $294,095 9 0
2017 $153,334 10 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $476,294 21 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE DOSES OF INHALED QBW276 Novartis Pharmaceuticals Corporation $434,574 0
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE DOSES OF INHALED QBW276 IN PATIENTS WITH CYSTIC FIBROSIS Novartis Pharmaceuticals Corporation $32,669 0
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MULTIPLE DOSES OF QBW251 IN PATIENTS WITH COPD Novartis Pharmaceuticals Corporation $9,051 0

Top Doctors Receiving Payments for QBW276

Doctor Specialty Location Total Records
Unknown — Boston, MA $476,294 21

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $476,294
  • Total Doctors 0
  • Transactions 21

About QBW276

QBW276 is a drug associated with $476,294 in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.

Payment data is available from 2017 to 2019. In 2019, $28,866 was paid across 2 transactions to 0 doctors.

The most common payment nature for QBW276 is "Unspecified" ($476,294, 100.0% of total).

QBW276 is associated with 3 research studies, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE DOSES OF INHALED QBW276" ($434,574).